TKL Research appoints vp of operational excellence
US CRO hires Kevin Vernarec
Vernarec has previously held a variety of operational roles at multinational CROs covering global project management, clinical operations, proposals, budgeting and costing, CTMS and EDC systems implementation, vendor management, process re-engineering and project planning and tracking.
Headquartered in Rochelle Park, New Jersey, TKL Research provides clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialised research clinics.
You may also like
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Design & Build
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy
The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours